How to Monitor Pregnancy on ADHD Medication Treatment
How should clinicians monitor a pregnant patient who continues stimulant or nonstimulant ADHD medication?
Some pregnant patients will continue ADHD pharmacotherapy because discontinuation may worsen functioning or symptoms. When medication is continued, this study supports focused monitoring across gestation for the obstetric domains most consistently associated with stimulant and nonstimulant exposure.
-
Identify the medication class being continued
Determine whether the patient is continuing a stimulant or a nonstimulant, because the pattern of associated obstetric risk differed by class. The study evaluated stimulant exposure separately from nonstimulant exposure and also compared the 2 classes directly.
-
Establish baseline maternal risk status early in pregnancy
Document advanced maternal age status, race and ethnicity, smoking or drinking status, and comorbid obesity or overweight, hypertension, depression, anxiety, bipolar disorder, ADHD, and substance use disorder at the start of pregnancy care. These baseline factors were part of the study’s adjustment model because they were common in medication-exposed patients and may compound obstetric risk.
-
Monitor blood pressure-related complications across gestation
Follow patients longitudinally for gestational hypertension and preeclampsia or eclampsia if stimulant or nonstimulant treatment is continued. Compared with no medication, both stimulant and nonstimulant exposure were associated with increased risk for hypertensive disorders, and the article specifically recommends monitoring blood pressure across gestation.
-
Watch for placental complications
Maintain clinical vigilance for placenta previa and placental abruption during pregnancy, with attention to how risk differs by medication class. Stimulant exposure was associated with increased risk of placenta previa versus no medication and higher odds of placenta previa than nonstimulant exposure, while nonstimulant exposure showed a strong higher-risk signal for placental abruption versus no medication.
-
Track fetal growth patterns
Monitor fetal growth longitudinally because medication exposure was associated with abnormalities in both directions depending on class. Stimulant exposure was associated with increased risk of intrauterine growth restriction versus no medication and higher odds of large for gestational age versus both no medication and nonstimulant exposure, while nonstimulant exposure was associated with increased risk of IUGR and lower odds of large for gestational age versus no medication.
-
Monitor for timing-of-birth complications
Follow for preterm delivery and spontaneous abortion during pregnancy when stimulant or nonstimulant treatment continues. Both classes were associated with increased risk of these outcomes versus no medication, and nonstimulant exposure was associated with higher odds of preterm delivery than stimulant exposure.
-
Reassess treatment and symptoms throughout pregnancy
Revisit the medication plan across gestation as symptoms, functioning, sleep disruption, nausea or appetite changes, and blood pressure evolve. The discussion notes that pregnancy may trigger discontinuation, restarting, or formulation changes, and recommends longitudinal monitoring that includes treatment changes, symptoms, blood pressure, and fetal growth.
Clinical Considerations
- The study does not provide a formal monitoring schedule or testing protocol, only the obstetric domains that were associated with medication exposure.
- Medication groups included heterogeneous agents and formulations, and the study did not analyze risk for individual stimulant formulations or individual nonstimulant agents.
- The observed associations may reflect unmeasured factors such as adherence, nutrition, social support, severity or timing of substance use, or other pregnancy-related variables.
- Most associations were modest in magnitude, so the clinical meaning of absolute risk likely varies by patient and by outcome.
Bottom Line
If ADHD medication is continued during pregnancy, monitor throughout gestation for blood pressure complications, placental complications, fetal growth abnormalities, and preterm birth risk rather than focusing on a single outcome.
